(Red)	41_5/01	Pub.605)
(RG)	41-3/71	rub.003)

FORM 11-3

11-17

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jurgen BERNHARDT ET AL.

Serial No.:

10/512,737

Filed:

October 27, 2004

For:

TRANSPORT SYSTEM IN BIOLOGICAL SYSTEMS

Hon. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)

NOTE:	A terminal disclaimer should not accompany a petition based on unintentional abandonment. Notice of July 9, 1985 (1056 O.G. 60-61).					
NOTE:	An application surcharge	An application abandoned under 37 CFR 1.53(d) for failure to timely provide the appropriate filing fee, oath or declaration and/or surcharge may not be revived under the procedure of 37 CFR 1.137(b).				
1.	This application became abandoned on <u>February 20, 2006</u> .					
NOTE:	Extensions under 37 CFR 1.136 are available only if asked for "prior to or with the response." Accordingly, if the question of abandonment arises when the provisions of §1.136 can no long be used then the application is abandoned with the unextended time for response expired. Therefore, no extension fees are due on a petition for revival.					
2.	This petition is filed:					
	\mathbf{x}	within one year of the date of abandonment.				
NOTE:	is due to a	y limited conditions a petition to revive for unintentional abandonment may exceed the one year limit when abandonment ction or inaction by the applicant and the PTO performs a positive documented official act which could lead a reasonable I to conclude that the action or inaction was appropriate. Notice of August 26, 1985 (O.G. 4).				
		within three months of the date of the first decision on a petition to revive under 37 CFR 1.137(a) which was filed within one year of the date of abandonment.				
		(check next box if applicable)				
		the three month period has been extended up to				
NOTE:	The non-statutory three month period may be extended up to four months if a petition for an extension of time and the fee set in 37 CFR 1.17 to (d) are filed with or prior to this petition.					

Certificate of Mailing (37 CFR 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 21, 2006.

Kelly Esnitia

-5/91 Pub.6	05)		FORM 11-3 11-17
3.	This application became abandoned unintentionally.		
4.	Proposed response		
		has beer	n filed.
	X	is attach	ned .
	Λ	15 4144011	(complete the following if applicable)
NOTE:	The PTO accepts the filing of a continuing application as a response under 37 CFR 1.137. To facilitate processing in such a case the petition to revive should specifically refer to the filing of a continuing application and also include an express abandonment the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing applicat Notice of May 13, 1983, 1031 O.G. 11-12.		
		the resp condition applicat	ponse is the filing of a continuation application having an express abandonment oned on the granting of a filing date to the continuing application co-pending with this tion.
5.	Fee (37 CFR 1.17(m))		
	Appli	ication Stati	us is:
		small bu	usiness entity-fee
			verified statement attached
			verified statement filed
		other th	an small entity-fee \$
6. Payment of fee:		ent of fee:	
		X	Enclosed please find check for \$ 1,500.00
		$\overline{\mathbf{x}}$	Charge Account <u>03-2468</u> for any additional fee required.
			Charge Account <u>03-2468</u> the sum of \$ A duplicate of this petition is attached.
Date	_{July} 2 (2006	
Date. <u>.</u>	July - 12	2000	
Reg. N	No:	26,048	SIGNATURE OF ATTORNEY JULIANOS
Tel. No.: (516) 365-9802		5) 365-9802	Edward R. Freedman type or print name of attorney
			COLLARD & ROE, P.C. 1077 Northern Blvd. P.O. Address
			Roslyn, NY 11576

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Jurgen BERHNARDT ET AL-2 PCT

SERIAL NO.: 10/512,737

RECEIVED

FILED:

OCTOBER 27, 2004

3 1 JUL 2006

PCT SERIAL NO.: PCT/EP03/03973

Legal Staff International Division

PCT FILING DATE: APRIL 16, 2003

TITLE:

TRANSPORT SYSTEM IN BIOLOGICAL SYSTEMS

RESPONSE TO NOTIFICATION OF ABANDONMENT

MAIL STOP PCT Hon. Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the enclosed copy of a "Notification of Abandonment" dated July 12, 2006, the Applicants are submitting herewith the following required documents:

- 1. Statement Under Rules 821(e), 821(f), 821(g), 825(b) & 825(d);
- Paper Copy of Sequence Listing;
- 3. Sequence Listing in Computer Readable Form (Diskette);
- 4. Copy of Notification of Abandonment;
- 5. Petition to Revive, plus check for \$1,500.00.

Now this application does contain a Statement that the content of the Sequence Listing information recorded in Computer Readable Form is identical to the written Paper Sequence Listing and includes no new matter, as required by CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Also enclosed is a copy of the "Sequence Listing" in Computer Readable Form which has now been submitted as required by 37 CFR 1.821(e).

For all these reasons, it is respectfully submitted that the present patent application is now in complete compliance with all the requirements for acceptance under 35 U.S.C. 371.

The enclosed Petition to Revive includes the Petition Fee of \$1,500.00. If any other fee is required, then the Commissioner of Patents and Trademarks is hereby authorized to charge any additional fee, or to credit any overpayment, to our Deposit Account No. 03-2468.

Respectfully submitted,

Jurgen BERNHARDT ET AL.

Attorneys for Applicants

Allison C. Collard, Reg. No. 22,532

Edward R. Fréedman, Reg. No. 26,048

Frederick J. Dorchak, Reg.No.29,298

COLLARD & ROE, P.C. 1077 Northern Boulevard Roslyn, New York 11576 (516) 365-9802

ERF:lgh

Enclosures: 1. Statement Under Rules 821(e), 821(f), 821(g), 825(b) & 825(d);

- 2. Paper Copy of Sequence Listing;
- 3. Sequence Listing in Computer Readable Form
 (Diskette);
- 4. Copy of Notification of Abandonment
- 5. Petition to Revive, plus fee check of \$1,500.00.

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 21, 2006.

07/28/2006 ATRAN1 00000125 10512737 01 FC:1453

1500.00 DP

R:\Patents\B\BERNHARDT ET AL - 2 PCT\Response to Notice of Abandonment.wpd

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Jurgen BERHNARDT ET AL-2 PCT

SERIAL NO.: 10/512,737

FILED:

OCTOBER 27, 2004

PCT SERIAL NO.: PCT/EP03/03973

PCT FILING DATE: APRIL 16, 2003

TITLE:

TRANSPORT SYSTEM IN BIOLOGICAL SYSTEMS

STATEMENT UNDER RULES 821(e), 821(f), 821(g), 825(b) & 825(d)

MAIL STOP PCT

Hon. Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

It is stated that the content of the enclosed paper Sequence Listing and computer readable form Sequence Listing are the same and contain no new matter as required by U.S.P.T.O. Rules 821(e), 821(f), 821(g), 825(b) & 825(d).

Respectfully submitted,

Jurgen BERNHARDT EI

COLLARD & ROE, P.C. 1077 Northern Boulevard Roslyn, New York 11576

(516) 365-9802

ERF: lgh

Allison C. Collard, Reg. No. 22, 532

Edward R. Freedman, Reg. No. 26,048 Frederick J. Dorchak, Reg.No.29,298

Attorneys for Applicants

Enclosures: Sequence Listing and diskette

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 21, 2006.

R:\Patents\B\BERNHARDT ET AL - 2 PCT\Seq.List.Statement.wpd

```
Sequence listing
<110> BioTeSys GmbH
  Schelztorstrasse 54-56
  D 73728 Esslingen
  GERMANY
<120> transport system in biological systems
<150> A 656/2002
<151> 2002-04-29
<160> 15
<210>1
<211>6
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 1
Gly Arg Gly Asp Ser Pro
                 5
1
<210>2
<211>5
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 2
Tyr Ile Glu Ser Arg
1
               5
<210>3
<211>5
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 3
Ala Asp Gly Glu Ala
1
<210>4
<211>6
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 4
Val Arg Leu Leu Asn Asn
```

5

```
<210>5
<211>8
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 5
Val Arg Leu Leu Asn Asn Trp Asp
1
<210>6
<211>8
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 6
Gly Arg Val Arg Leu Leu Asn Asn
                 5
1
<210>7
<211>6
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 7
Met Thr Ala Gly Ala Gly
1
<210>8
<211>6
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 8
Leu Ser Gly Ala Leu Arg
                 5
1
<210>9
<211>22
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 9
```

```
Ile Val Ala Ile Leu Ile Cys Ile Leu Ile Leu Leu Thr Met Val Leu
                                10
                                                     15
               5
Leu Phe Val Met Trp Met
             20
<210> 10
<211>12
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 10
Ile Val Ala Ile Leu Ile Cys Ile Leu Ile Leu Leu
                                 10
1
<210>11
<211>18
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400>11
Ile Val Ala Ile Leu Ile Cys Ile Leu Ile Leu Leu Thr Met Val Leu
                                                     15
                                 10
1
               5
Leu Phe
<210> 12
<211>6
<212> PRT
<213> Artificial sequence
<223> Oligopeptide Chemically Synthesized
<400> 12
Ile Val Ala Ile Leu Ile
1
<210> 13
<211>6
<212> PRT
<213> Artificial sequence
<220>
<223> Oligopeptide Chemically Synthesized
<400> 13
Cys Ile Leu Ile Leu Leu
                5
<210> 14
<211>6
<212> PRT
<213> Artificial sequence
```



United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTY DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. **BERNHARDT ET AL 2 PCT** 10/512,737 Jurgen Bernhardt

INTERNATIONAL APPLICATION NO.

PCT/EP03/03973

I.A. FILING DATE PRIORITY DATE

04/16/2003 04/29/2002

CONFIRMATION NO. 1552

ABANDONMENT/TERMINATION

LETTER

OC000000019573413

25889 WILLIAM COLLARD COLLARD & ROE, P.C. 1077 NORTHERN BOULEVARD ROSLYN, NY 11576

Date Mailed: 07/12/2006

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

 Applicant has failed to properly respond to Notification of Missing Requirements dated 05/02/05. See attached Raw Sequence Listing Error Report dated 03/22/06.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

SINC Employment Systems Hearth

CAN SECTION OF THE SAUCE OF THE

The Biotechnology Systems Branch of the Scientific and Technical Information Genter (STIC) detected errors when processing the following computer readable

form:

Application Serial Number:

Source:

alain aanak

Date Processed by STIC:

:10/5]2₁737

3-22-06

randinar Gerena

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
 U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street,
 Alexandria, VA 22314

Revised 01/10/06

STAC Englydimental Systems Beams

NAW SECOUTAYOF HISTORY HIDRRORANGEORY

The Biotechnology Systems Branch of the Scientific and Technical Information
Genter (STIC) detected errors when processing the following computer readable
form:

:=::

Application Serial Number:

Source:

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
 U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street,
 Alexandria, VA 22314

Revised 01/10/06

IAP7 Rec'd PCT/PTO 31 MAR 2006



PCT

RAW SEQUENCE LISTING

DATE: 03/22/2006

PATENT APPLICATION: US/10/512,737

4 <110> APPLICANT: BioTeSys GmbH

TIME: 15:36:45

Input Set : A:\PTO.SS.txt

Output Set: N:\CRF4\03222006\J512737.raw

```
Schelztorstrasse 54-56
            D 73728 Esslingen
     8
            GERMANY
    10
    13 <120> TITLE OF INVENTION: transport system in biological systems
--> 16 <140> CURRENT APPLICATION NUMBER: US/10/512,737
--> 16 <141> CURRENT FILING DATE: 2004-10-27
   0 (<130> FILE REFERENCE: D)
    16 <150> PRIOR APPLICATION NUMBER: A 656/2002
                                                                   DECO SO CATTELY
    18 <151> PRIOR FILING DATE: 2002-04-29
                                                                   Conversed Limitaria Necdoca
    21 <160> NUMBER OF SEQ ID NOS: 15
RRORED SEQUENCES
 -> 24 <210> SEQ ID NO: 1 <211>6 <212
                                            <213> Artificial sequence
    27 <220> FEATURE:
    29 <223 > OTHER INFORMATION: Qligopertide
--> 32 <211> LENGTH:
--> 32 <212> TYPE:
 -> 32 <213> ORGANISM:
    32 <400> SEQUENCE: 1
    34 Gly Arg Gly Asp Ser Pro
   35 1
--> 38 <210> SEQ ID NO: 2 <211>5 <212>-PRT <213> Artificial sequence
    41 <220> FEATURE:
    43 <223 > OTHER INFORMATION Oligopeptide
--> 48 <211> LENGTH:
 -> 48 <212> TYPE:
-> 48 <213> ORGANISM:
    48 <400> SEQUENCE: 2
   50 Tyr lie Glu Ser Arg
    54 <210> SEQ ID NO: 3
    56 <211> LENGTH: 5
    58 <212> TYPE: PRT
    60 <213> ORGANISM: Artificial sequence
    63 <220> FEATURE:
    65 <223> OTHER INFORMATION Oligopeptide
    68 <400> SEQUENCE: 3
   70 Ala Asp Gly Glu Ala
                 B
 -> 71 1
    74 <210> SEQ ID NO: 4
```

DATE: 03/22/2006

TIME: 15:36:45

```
Osme errors
                   Input Set : A:\PTO.SS.txt
                   Output Set: N:\CRF4\03222006\J512737.raw
   76 <211> LENGTH: 6
   78 <212> TYPE: PRT
   80 <213> ORGANISM: Artificial sequence
   83 <220> FEATURE:
   85 <223 > OTHER INFORMATION: Of igopeptide
   88 <400> SEQUENCE: 4
   90 Val Arg Leu Leu Asn Asn
                 25
  > 91 1
   95 <210> SEQ ID NO: 5
   97 <211> LENGTH: 8
   99 <212> TYPE: PRT
   101 <213> ORGANISM: Artificial sequence
   104 <220> FEATURE:
   106 <223> OTHER INFORMATION: Oligopeptide
   109 ATOP> SEQUENCE: 5
 -> 111 Vai Arg Leu Leu Agn-Asn Trp-Asp
  > 122 1
    115 <210> SEQ ID NO: 6
   117 <211> LENGTH: 8
   119 <212> TYPE: PRT
   121 <213> ORGANISM: Artificial sequence
id . 124 <220> FEATURE:
    126 <223 > OTHER INFORMATION (Oligopeptide)
    129 <400> SEQUENCE: 6
--> 131 Gly Arg Val Arg Leu Leu Asri) Asn
                  78
--> 132 1
   135 <210> SEQ ID NO:
   137 <211> LENGTH: 6
   139 <212> TYPE: PRT
   142 <213> ORGANISM: Artificial segmence
    145 <220> FEATURE:
    147 <223> OTHER INFORMATION: QLigopeptide
   150 <400> SEQUENCE: 7
   152 Met Thr Ala Gly Ala Gly
                 ×
--> 153 1
    156 <210> SEQ ID NO: 8
    158 <211> LENGTH: 6
   161 <212> TYPE: PRT
    163 <213> ORGANISM: Artificial sequence
    166 <220> FEATURE:
    168 <223> OTHER INFORMATION: Oligopeptide
    171 <400> SEQUENCE: 8
    173 Leu Ser Gly Ala Leu Arg
--> 174 1 5/
--> 177 <210> SEQ ID NO: 9 <211> 22 <212> PRT <213> Artificial sequence
    180 <220> FEATURE:
    182 <223> OTHER INFORMATION: Oligopeptide
--> 185 <211> LENGTH:
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/512,737

--> 185 <212> TYPE:

DATE: 03/22/2006

PATENT APPLICATION: US/10/512,737 TIME: 15:36:45 Invalidad Acids. Input Set : A:\PTO.SS.txt Output Set: N:\CRF4\03222006\J512737.raw --> 185 <213> ORGANISM: 185 <400> SEQUENCE: 9 Vai) Ala (lie) Leu (lie) Cys (tie) Leu (lie) Leu Leu Thr Met Val Leu Leu Phe Val Met Tm Met 180 1 5/10/15 20 --> 193 <210> SEQ ID NO: 10 <211>12 <212> PRT <213> Artificial sequence 196 <220> FEATURE: 198 <223> OTHER INFORMATION: (Oiigopeptide --> 201 <211> LENGTH: --> 201 <212> TYPE: --> 201 <213> ORGANISM: 201 TROUSEQUENCE 10 rys(tie Leu(tie Leu Leu 203 (lie Vai) Ala(tie) Leu tie 10 204 --> 209 <210> SEQ ID NO: 11 <211>18 <212> PRT <213> Artificial sequence 212 <220> FEATURE: ino acids 214 <223> OTHER INFORMATION: Oligopeptide --> 217 <211> LENGTH: --> 217 <212> TYPE: --> 217 <213> ORGANISM: Patent-IN
SOFtware
SOFtware
WAS Used;
WAS Used;
PIS contract
Mark
Spencer
at 571-217 400> SEQUENCE Cys (lie Leu lie Leu Leu Thr Met Val Leu Leu Phe 218 tie Wal Ala tie 18/5 220 1 --> 223 <210> SEQ ID NO: 12 <211>6 <212> PRT <213> Artificial sequence 226 <220> FEATURE: 228 <223> OTHER INFORMATION: Oligopeptide --> 231 <211> LENGTH: --> 231 <212> TYPE: --> 231 <213> ORGANISM: 231 5400> SEQUENCE: 12 233 (tie) Val Ala (tie) 236 T --> 239 <210> SEQ ID NO: 13 <211>6 <212> PRT <213> Artificial sequence 242 <220> FEATURE: 244 <223 > OTHER INFORMATION: Oligopeptide --> 247 <211> LENGTH: --> 247 <212> TYPE: --> 247 <213> ORGANISM: 247 <400 SEQUENCE: 13 249 Cys/tie/Leu tie/Leu Leu 250 1 8 253 <210> SEQ ID NO: 14 255 <211> LENGTH: 6 257 <212> TYPE: PRT 259 <213> ORGANISM: Artificial sequence 2510, 262 <220> FEATURE: 264 <223> OTHER INFORMATION: Øligopeptide 267 <400> SEQUENCE: 14 269 Thr Met Val Leu Leu Phe --> 270 1

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/512,737

DATE: 03/22/2006

US/10/512,737 TIME: 15:36:45

Input Set : A:\PTO.SS.txt

Output Set: N:\CRF4\03222006\J512737.raw

273 <210> SBQ ID NO: 15

275 <211> LENGTH: 6

277 <212> TYPE: PRT

279 <213> ORGANISM: Artificial sequence-

283 <220> FEATURE:

285 <223 > OTHER INFORMATION Oligopeptide

288 <400> SEQUENCE: 45

--> 290 Leu Phe Val Met Tm Met

--> 291 1

. 1

3/22/2006

RAW SEQUENCE LISTING ERROR SUMMARY

PATENT APPLICATION: US/10/512,737

DATE: 03/22/2006

TIME: 15:36:46

Input Set : A:\PTO.85/.txt

Output Set: N:\CRF4\03222006\J512737.raw

avalid Line Length:

ne rules require that a line not exceed 72 characters in length. This includes spaces.

eq#:9; Line(s) 189

VERIFICATION SUMMARYDATE: 03/22/2006PATENT APPLICATION: US/10/512,737TIME: 15:36:46

Input Set : A:\PTO.SS.txt

Output Set: N:\CRF4\03222006\J512737.raw

```
:16 M:270 C: Current Application Number differs, Replaced Current Application No
:16 M:271 C: Current Filing Date differs, Replaced Current Filing Date
:0 M:201 W: Mandatory field data missing, <130> FILE REFERENCE
:24 M:212 E: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 1 <211>6 <212> PRT
213> Artificial sequence
:32 M:282 E: Numeric Field Identifier Missing, <211> is required.
:32 M:282 E: Numeric Field Identifier Missing, <212> is required.
:32 M:282 E: Numeric Field Identifier Missing, <213> is required.
:38 M:212 E: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 2 <211>5 <212> PRT
213> Artificial sequence
:48 M:282 E: Numeric Field Identifier Missing, <211> is required.
:48 M:282 B: Numeric Field Identifier Missing, <212> is required.
:48 M:282 B: Numeric Field Identifier Missing, <213> is required.
:71 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:3
:91 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:4
:111 M:330 E: (2) Invalid Amino Acid Designator, NUMBER OF INVALID KEYS:1
:112 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:5
:131 M:333 E: Wrong sequence grouping, Amino acids not in groups!
:131 M:330 E: (2) Invalid Amino Acid Designator, NUMBER OF INVALID KEYS:1
:132 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:6
:153 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:7
:174 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:8
:177 M:212 E: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 9 <211> 22 <212> PRT
213> Artificial sequence
:185 M:282 E: Numeric Field Identifier Missing, <211> is required.
:185 M:282 E: Numeric Field Identifier Missing, <212> is required.
:185 M:282 E: Numeric Field Identifier Missing, <213> is required.
:193 M:212 E: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 10 <211>12 <212> PRT
213> Artificial sequence
:201 M:282 B: Numeric Field Identifier Missing, <211> is required.
:201 M:282 B: Numeric Field Identifier Missing, <212> is required.
:201 M:282 B: Numeric Field Identifier Missing, <213> is required.
:209 M:212 B: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 11 <211>18 <212> PRT
213> Artificial sequence
:217 M:282 B: Numeric Field Identifier Missing, <211> is required.
:217 M:282 E: Numeric Field Identifier Missing, <212> is required.
:217 M:282 B: Numeric Field Identifier Missing, <213> is required.
:223 M:212 B: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 12 <211>6 <212> PRT
213> Artificial sequence
:231 M:282 B: Numeric Field Identifier Missing, <211> is required.
:231 M:282 E: Numeric Field Identifier Missing, <212> is required.
:231 M:282 B: Numeric Field Identifier Missing, <213> is required.
:239 M:212 B: (34) Invalid or duplicate Sequence ID Number, SEQ ID NO: 13 <211>6 <212> PRT
213> Artificial sequence
:247 M:282 E: Numeric Field Identifier Missing, <211> is required.
:247 M:282 E: Numeric Field Identifier Missing, <212> is required.
:247 M:282 B: Numeric Field Identifier Missing, <213> is required.
:270 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:14
:290 M:333 E: Wrong sequence grouping, Amino acids not in groups!
:290 M:330 E: (2) Invalid Amino Acid Designator, NUMBER OF INVALID KEYS:1
```

:291 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:15